Reata Pharmaceuticals and members of its board of directors were hit with a shareholder lawsuit on Aug. 28 in Delaware District Court over the company’s proposed acquisition by Biogen for $7.3 billion. The suit, filed by Long Law on behalf of Philip Stone, alleges that the proxy statement filed in support of the deal contains false information. Counsel have not yet appeared for the defendants. The case is 1:23-cv-00940, Stone v. Reata Pharmaceuticals Inc. et al.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
